Evidence map›Paper›PMID 34671867›Full record

ArticleHandbook of experimental pharmacology2022

Immunosuppression and Heart Transplantation.

Nilay Sutaria, Lynne Sylvia, David DeNofrio

Abstract read
PubMed Publisher
In one paragraph

Article in Handbook of experimental pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Nilay SutariaCardiovascular Center, Tufts Medical Center, Boston, MA, USA.
Lynne SylviaCardiovascular Center, Tufts Medical Center, Boston, MA, USA.
David DeNofrioCardiovascular Center, Tufts Medical Center, Boston, MA, USA. ddenofrio@tuftsmedicalcenter.org.
Tufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the first human heart transplant in 1967, immense advancements have been made in the field of immunosuppression. This chapter provides an in-depth analysis of the use of immunosuppressive agents in heart transplant recipients. Evidence regarding maintenance immunosuppressive regimens, the efficacy of induction immunosuppression and corticosteroid weaning, as well as the use of distinct immunosuppression regimens within select patient populations is summarized. This chapter helps elucidate the data regarding contemporary protocols in cardiac transplantation.

Indexed as

Calcineurin InhibitorsHeart TransplantationCyclosporineGraft RejectionHumansImmunosuppression TherapyImmunosuppressive AgentsMycophenolic AcidSirolimusCalcineurin InhibitorsCyclosporineImmunosuppressive AgentsMycophenolic AcidSirolimusAzathioprineCalcineurin inhibitorsCancerCardiacCorticosteroidCyclosporineEverolimusHeartImmuneImmunosuppressionInductionMaintenancemTOR inhibitorsMycophenolateOrthotopicPrednisoneRejectionSirolimusSteroidTacrolimusTransplantVasculopathy

Identifiers

PMID34671867
OpenAlexW3205977094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.